Clinical Trial Detail

NCT ID NCT03897881
Title An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Patients With High-Risk Melanoma (KEYNOTE-942)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors ModernaTX, Inc.
Indications

skin melanoma

Therapies

mRNA-4157 + Pembrolizumab

Pembrolizumab

Age Groups: adult senior

No variant requirements are available.